Additionally, GPC3-targeted antibody-drug conjugates (ADCs), such as codrituzumab (GC33) (e.g., NCT01507168), have shown specific tumor localization and acceptable toxicity profiles in clinical studies, though their efficacy may be further enhanced by combinatorial approaches. The gene discussed is GPC3; the disease is neoplasm.